The slow recovery in vaccination rates and lower patient visits to physicians weighed on the top-line, although prudent cost management ensured margin expansion in Q3. While rising COVID cases could postpone the recovery in the vaccines segment, sturdy demand for the newer class of respiratory and HIV drugs should make up for the shortfall. A strengthening presence in the oncology and lupus space is also a positive. Favourable results from COVID-related trials could be a needle-mover in Q4.
30 Oct 2020
Speciality pharma to drive Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Speciality pharma to drive Q4
GSK plc (GSK:LON) | 1,587 55.5 0.2% | Mkt Cap: 65,769m
- Published:
30 Oct 2020 -
Author:
Rishabh Kochar -
Pages:
4
The slow recovery in vaccination rates and lower patient visits to physicians weighed on the top-line, although prudent cost management ensured margin expansion in Q3. While rising COVID cases could postpone the recovery in the vaccines segment, sturdy demand for the newer class of respiratory and HIV drugs should make up for the shortfall. A strengthening presence in the oncology and lupus space is also a positive. Favourable results from COVID-related trials could be a needle-mover in Q4.